Search

Your search keyword '"Deodhar A"' showing total 1,569 results

Search Constraints

Start Over You searched for: Author "Deodhar A" Remove constraint Author: "Deodhar A" Topic medicine Remove constraint Topic: medicine
1,569 results on '"Deodhar A"'

Search Results

1. Documentation of Assessment of Spiritual Concerns of Adult Advanced Cancer Patients: An Audit in a Hospital-based Specialist Palliative Care Service

2. Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models

3. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy

4. Development of a model of Home-based Cancer Palliative Care Services in Mumbai - Analysis of Real-world Research Data over 5 Years

5. Hepatic tuberculosis masquerading as malignancy

6. A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

7. Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity

8. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic

9. Demyelinating Disease After Exposure to Tumor Necrosis Factor α Inhibitors

10. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

11. Serous endometrial intraepithelial carcinoma: A clinico-pathological study of 48 cases and its association with endometrial polyps – A tertiary care oncology centre experience

12. Psychological distress in primary caregivers of children with cancer during COVID‐19 pandemic‐A single tertiary care center experience

13. Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study

14. Expression dynamics of S locus genes defining self-incompatibility in tetraploid potato (Solanum tuberosum L.) Cv. Kufri Girdhari

15. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

16. STABILITY-INDICATING HPTLC METHOD FOR DETERMINATION OF DACLATASVIR IN PHARMACEUTICAL DOSAGE FORM

17. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

18. Clinical and Laboratory Characteristics of Patients with Peritoneal Tuberculosis Mimicking Advanced Ovarian Cancer

20. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience

21. Deprescribing opportunities for elderly inpatients in an academic, safety-net health system

22. The impact of the COVID-19 pandemic on people with rheumatic and musculoskeletal diseases: insights from patient-generated data on social media

23. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey

24. Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial

25. The Palliative Care—Promoting Access and Improvement of the Cancer Experience (PC-PAICE) Project in India: A Multisite International Quality Improvement Collaborative

27. Efficacy of Coronally Advanced Flap with and Without Augmentation in The Management of Gingival Recession: A Systematic Review

28. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

29. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation

30. Analysis of the surgical management of skin cancer in the nonagenarian population: Twenty-five year data analysis from a single centre

31. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature

33. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

34. Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

35. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

36. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial

37. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial

38. Understanding differences between men and women with axial spondyloarthritis

39. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

40. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials

41. Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States

42. Direct Chiral HPLC-MS/MS Method for Determination of R-Lacosamide in Human Plasma

43. Reliability of conventional Papanicolaou smear in diagnosing bacterial vaginosis among women with clinical genital infection

44. Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real-world study

45. RIFM fragrance ingredient safety assessment, carvyl acetate, CAS registry number 97-42-7

46. RIFM fragrance ingredient safety assessment, α-pinene, CAS Registry Number 80-56-8

47. RIFM fragrance ingredient safety assessment, 4,7-dimethyloct-6-en-3-one, CAS Registry Number 2550-11-0

48. RIFM fragrance ingredient safety assessment, methyl furfuryl disulfide, CAS Registry Number 57500-00-2

49. RIFM fragrance ingredient safety assessment, α-cyclohexylidene benzeneacetonitrile, CAS Registry Number 10461-98-0

50. Polymorphism of interleukin-6 -174 G/C (rs1800795) & the corresponding interleukin-6 level as a prognostic marker of cervical cancer

Catalog

Books, media, physical & digital resources